Quell Therapeutics Showcases Groundbreaking CAR-Treg Developments
Quell Therapeutics Ltd, a pioneering force in engineered T-regulatory (Treg) cell therapies, is set to unveil significant advancements at major international medical gatherings. These presentations at influential congresses in the fields of gene therapy and liver diseases will spotlight their innovative research and findings.
Upcoming Presentations in the Medical Community
At the prestigious European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, set to take place in an inspiring city, Quell will present two key opportunities to engage with their latest research on CAR-Treg therapies. The oral presentation will emphasize their LIBERATE study, focusing on the therapeutic potential of their lead candidate QEL-001 in liver transplant recipients. This study aims to establish donor-specific tolerance, a significant barrier faced in previous trials.
Safety and Efficacy Insights from LIBERATE Study
The presentations will reveal promising data on the safety cohort of the LIBERATE clinical trial. Notably, QEL-001 has been shown to be well-tolerated by patients, exhibiting cell persistence up to six months post-infusion. The molecular markers FOXP3 and HELIOS were utilized to confirm the stability of these cells, a crucial factor for their effectiveness in clinical applications.
Collaboration for Innovation
Another aspect of Quell's research involves their development of allogenic Treg cells derived from induced pluripotent stem cells (iPSCs). This advancement is expected to broaden the scope of treatments for autoimmune and inflammatory diseases. Collaborating closely with Cellistic, Quell is focusing on refining the differentiation process necessary to successfully generate these potent immune cells.
Details of the Congress Presentations
The oral presentation at ESGCT will highlight:
Abstract Title: CAR-Treg cell therapy to induce tolerance in liver transplantation – LIBERATE clinical trial
Abstract Number: OR084
Date & Time: Thursday, 3:30 p.m. - 5:30 p.m. (CET)
Session: Immunotherapy and CAR-T Cells II
Presenter: Rupert Kenefek, PhD, Senior Director of Translational Sciences at Quell Therapeutics.
Additionally, a poster presentation will delve into:
Abstract Title: Development and characterization of iPSC-derived regulatory T cells – Towards an allogenic cell therapy for the treatment of autoimmunity and inflammatory conditions
Abstract Number: PO368
Date & Time: Wednesday, 1:30 p.m. - 3:00 p.m. (CET)
Presenter: Sophie Howson, Scientist at Quell Therapeutics.
Exploring The Liver Meeting
The Quell Therapeutics team is also preparing to present at The Liver Meeting, an esteemed event in the field of hepatology. Here, they will share insights from their ongoing study on QEL-001, further emphasizing the product's safety profile and potential efficacy in liver transplant scenarios.
Key Aspects of The Liver Meeting Presentation
Details regarding the poster presentation include:
Abstract Title: The Safety and Tolerability of QEL-001, an Autologous Chimeric Antigen Receptor (CAR) T Regulatory (Treg) Cell Therapy, in Liver Transplantation – A Safety Cohort in the LIBERATE Study
Abstract Number: 1386
Date & Time: Saturday, 1:00 p.m. - 2:00 p.m. (PST)
Presenter: Alberto Sanchez-Fueyo, Professor of Hepatology at King’s College London and Honorary Transplant Hepatology Consultant.
About Quell Therapeutics
Quell Therapeutics is at the forefront of developing Treg cell therapies. Their innovative approach aims to optimize the immune suppressive properties of Tregs to tackle serious medical conditions linked to immune dysfunction. Leveraging their proprietary Foxp3 Phenotype Lock™ technology and advanced multi-modular platform, they are developing therapies with enhanced durability and effectiveness.
The company’s lead candidate, QEL-001, is in an exciting Phase 1/2 clinical trial focused on operational tolerance post-liver transplantation—research that could significantly reduce the need for long-term immunosuppression. In addition to their liver-focused research, Quell is also advancing other therapeutic strategies in neuroinflammatory and autoimmune diseases. This direction ensures that Quell remains a significant player in the biopharmaceutical landscape.
Frequently Asked Questions
What is Quell Therapeutics focusing on in their upcoming presentations?
Quell Therapeutics is focusing on their innovative CAR-Treg therapies, including pivotal data on their lead candidate QEL-001 in liver transplant patients.
How does QEL-001 work in liver transplantation?
QEL-001 aims to induce donor-specific tolerance, therefore allowing liver transplant recipients to avoid long-term immunosuppressive medications by ensuring the body's acceptance of the new organ.
What are the key outcomes from the LIBERATE study?
Results show that QEL-001 is well-tolerated and maintains cell persistence and stability for up to six months post-treatment, which is promising for its continued development.
How is Quell innovating Treg cell therapies?
Quell is innovating through the development of iPSC-derived Treg cells, enhancing the potential to create allogenic therapies targeted at autoimmune diseases.
Who is presenting at the congresses?
Notable presentations will be given by Rupert Kenefek, PhD, and Alberto Sanchez-Fueyo, bringing expertise from leading academic and clinical backgrounds.
